Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,468JPY
7:00am BST
Change (% chg)

¥-26 (-0.58%)
Prev Close
¥4,494
Open
¥4,450
Day's High
¥4,485
Day's Low
¥4,375
Volume
8,024,700
Avg. Vol
4,667,403
52-wk High
¥6,693
52-wk Low
¥4,203

Latest Key Developments (Source: Significant Developments)

Takeda Pharmaceutical and ASKA Pharmaceutical enter into licensing agreement for relugolix in women's health indications
Thursday, 31 May 2018 

May 31 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it and ASKA Pharmaceutical Co Ltd <<<4514.T>>> announced today that they entered inter a licensing agreement to grant ASKA exclusive commercialization right for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan to maximize the product value of Takeda-owned relugolix.Based on this agreement, Takeda will receive upfront payment for granting the exclusive commercialization right for uterine fibroids and the exclusive development and commercialization rights for endometriosis in Japan as well as holding the right to receive royalties on sales.  Full Article

Proposed acquisition of Shire by Takeda Pharmaceutical
Tuesday, 8 May 2018 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Takeda Pharmaceutical Company Limited and Shire plc today announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire.Under the terms of the acquisition, each Shire shareholder will be entitled to receive $30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs.Shire shareholders will own about half of the combined group after the deal .  Full Article

Takeda Pharm CEO Weber Says Neuroscience Will Continue To Be A Core Area
Tuesday, 8 May 2018 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T> Chief Executive Officer Christophe Weber::NEUROSCIENCE WILL CONTINUE TO BE A CORE AREA.JOBS COULD BE IMPACTED.  Full Article

Takeda Says Notes Statement By Shire Regarding Revised Proposal, Deadline Extension
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T>::SAYS NOTES STATEMENT BY SHIRE PLC REGARDING REVISED PROPOSAL AND EXTENSION OF PUSU DEADLINE TO MAY 8, 2018.SAYS INTENDS TO MAINTAIN ITS WELL-ESTABLISHED DIVIDEND POLICY AND INVESTMENT GRADE CREDIT RATING.  Full Article

Shire announces Takeda's revised proposal of about 49 pounds per share
Wednesday, 25 Apr 2018 

April 24 (Reuters) - Shire Plc ::SHIRE ANNOUNCES REVISED PROPOSAL AND EXTENSION OF PUSU DEADLINE TO 8 MAY 2018.INDICATED TO TAKEDA WOULD BE WILLING TO RECOMMEND REVISED PROPOSAL TO SHAREHOLDERS SUBJECT TO SATISFACTORY RESOLUTION OF OTHER TERMS OF POSSIBLE OFFER.SATISFACTORY RESOLUTION OF OTHER TERMS OF POSSIBLE OFFER, INCLUDE COMPLETION OF RECIPROCAL DUE DILIGENCE BY SHIRE ON TAKEDA.REVISED PROPOSAL COMPRISES 0.839 NEW TAKEDA SHARES AND US$30.33 IN CASH FOR EACH SHIRE ORDINARY SHARE.REVISED PROPOSAL IMPLIES AN EQUIVALENT VALUE OF APPROXIMATELY £49 PER SHIRE ORDINARY SHARE.REVISED PROPOSAL COMPRISING OF £27.26 IN NEW TAKEDA SHARES; AND £21.75 IN CASH.REVISED PROPOSAL IS EQUIVALENT TO A VALUE OF APPROXIMATELY £46 BILLION FOR ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.CO SHAREHOLDERS WOULD BE ENTITLED TO ANY DIVIDENDS ANNOUNCED BY SHIRE IN ORDINARY COURSE PRIOR TO COMPLETION OF POSSIBLE TRANSACTION.ON DEAL COMPLETION, SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 50 PER CENT.OF THE ENLARGED TAKEDA AND THE NEW TAKEDA SHARES WILL BE LISTED IN JAPAN AND IN US THROUGH AN ADR PROGRAM.  Full Article

Takeda Confirms Made A Revised Proposal To Board Of Shire
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA STATEMENT REGARDING SHIRE PLC.CONFIRMS THAT IT HAS MADE A REVISED PROPOSAL TO BOARD OF SHIRE .  Full Article

Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Nektar Therapeutics ::NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS.NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL EACH MAINTAIN GLOBAL COMMERCIAL RIGHTS TO THEIR RESPECTIVE INVESTIGATIONAL MEDICINES.NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL SPLIT COSTS RELATED TO CLINICAL TRIAL.NEKTAR THERAPEUTICS - FIRST TRIAL IS EXPECTED TO START IN SECOND HALF OF 2018.NEKTAR - FIRST TRIAL TO EVALUATE COMBINATION OF EVERY 3-WEEK SCHEDULE OF NKTR-214 WITH ORAL DAILY DOSES OF TAK-659 IN PATIENTS WITH NON-HODGKIN LYMPHOMA.  Full Article

Shire Says Received Revised Proposal From Takeda On Possible Offer, Says Considering Its Position
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Shire Plc ::SHIRE PLC: STATEMENT RE REVISED PROPOSAL.RECEIVED A REVISED PROPOSAL FROM TAKEDA REGARDING A POSSIBLE OFFER FOR COMPANY ON 24 APRIL 2018.BOARD IS CONSIDERING ITS POSITION.CAN BE NO CERTAINTY THAT ANY FIRM OFFER FOR COMPANY WILL BE MADE NOR AS TO TERMS ON WHICH ANY FIRM OFFER MIGHT BE MADE.  Full Article

Takeda Is Said To Near Preliminary Agreement To Buy Shire- Bloomberg
Tuesday, 24 Apr 2018 

April 24 (Reuters) - :TAKEDA IS SAID TO NEAR PRELIMINARY AGREEMENT TO BUY SHIRE - BLOOMBERG, CITING SOURCES.  Full Article

Shire Says Considering Position With Respect To Fourth Proposal From Takeda
Friday, 20 Apr 2018 

April 20 (Reuters) - Shire Plc ::SHIRE PLC - STATEMENT RE PROPOSAL FROM TAKEDA PHARMACEUTICAL COMPANY LIMITED ("TAKEDA").SHIRE PLC - BOARD OF SHIRE IS CONSIDERING ITS POSITION WITH RESPECT TO FOURTH PROPOSAL AND WILL ISSUE A FURTHER ANNOUNCEMENT IN DUE COURSE.SHIRE PLC - CONFIRMS IT HAS RECEIVED A FOURTH PROPOSAL FROM TAKEDA ON 20 APRIL 2018 REGARDING A POSSIBLE OFFER FOR COMPANY.  Full Article

RPT-UPDATE 1-Wall St Week Ahead-International fund managers turn to financials, tech as trade worries rise

NEW YORK, June 15 The rising tensions over global trade policy are prompting some top-performing international fund managers to look for the companies that can emerge as winners.